AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.97 USD | -7.96% |
|
-43.97% | -69.98% |
| Apr. 12 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| Apr. 12 | Sector Update: Health Care | MT |
Financials (USD)
| Sales 2024 * | 284M | Sales 2025 * | 199M | Capitalization | 104M |
|---|---|---|---|---|---|
| Net income 2024 * | -154M | Net income 2025 * | -269M | EV / Sales 2024 * | 0.37 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.52 x |
| P/E ratio 2024 * |
-0.64
x | P/E ratio 2025 * |
-0.38
x | Employees | 389 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Agenus Inc.
More recommendations
More press releases
| 1 day | -7.96% | ||
| 1 week | -43.97% | ||
| Current month | -57.16% | ||
| 1 month | -53.09% | ||
| 3 months | -55.89% | ||
| 6 months | -75.76% | ||
| Current year | -69.98% |
1 week
4.78
9.22
1 month
4.7811.83
Current year
4.7818.98
1 year
4.7842.60
3 years
4.78135.80
5 years
4.78135.80
10 years
4.78203.20
| Managers | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director of Finance/CFO | 58 | 95-12-31 | |
Craig Winter
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director/Board Member | 66 | 16-05-16 | |
Susan Hirsch
BRD | Director/Board Member | 71 | 20-10-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.15% | 27 M€ | -7.00% | - | |
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 4.97 | -7.96% | 1,670,776 |
| 24-04-17 | 5.4 | -14.29% | 1,526,945 |
| 24-04-16 | 6.3 | -3.08% | 1,322,989 |
| 24-04-15 | 6.5 | -20.25% | 1,459,460 |
| 24-04-12 | 8.15 | -8.12% | 1,399,796 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.97
USD
Average target price
88.75
USD
Spread / Average Target
+1,685.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -69.98% | 104M | |
| -1.82% | 41.35B | |
| +44.25% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- AGEN Stock
